Clinical trial
Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and…
NCT00129753 · M.D. Anderson Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00129753 |
|---|---|
| Title | Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease |
| Official title | Phase II Study of Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hodgkin's Disease, Lymphoma |
| Intervention type | Drug |
| Interventions | Alemtuzumab (Campath-1H) |
| Enrollment | 0 |
| Start date | Jun 22, 2005 |
| Primary completion | Sep 5, 2006 |
| Completion | Sep 5, 2006 |
| First posted | Aug 12, 2005 |
| Last update posted | Nov 8, 2018 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: